Safety and Efficacy Study of Daclizumab High Yield Process to Treat Relapsing-Remitting Multiple Sclerosis (SELECT)

This study has been completed.
Sponsor:
Collaborator:
AbbVie
Information provided by (Responsible Party):
Biogen Idec
ClinicalTrials.gov Identifier:
NCT00390221
First received: October 17, 2006
Last updated: September 12, 2013
Last verified: May 2013
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: August 2011
  Primary Completion Date: May 2011 (Final data collection date for primary outcome measure)
No publications provided by Biogen Idec

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):